DURECT Corporation (DRRX)
-NasdaqGM 0.81 
0.02(2.41%) Jun 17, 4:00PM EDT
| Prev Close: | 0.83 |
|---|
| Open: | 0.82 |
|---|
| Bid: | 0.77 x 400 |
|---|
| Ask: | 1.09 x 100 |
|---|
| 1y Target Est: | 2.75 |
|---|
| Beta: | 1.17 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.80 - 0.82 |
|---|
| 52wk Range: | 0.61 - 1.85 |
|---|
| Volume: | 210,516 |
|---|
| Avg Vol (3m): | 632,864 |
|---|
| Market Cap: | 82.53M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alkermes Changing The Standard Of Care For Schizophreniaat Seeking Alpha(Thu, Jun 13)
- SmithOnStocks Opines Week Of June 2, 2013at Seeking Alpha(Mon, Jun 3)
- FDA Painkiller Abuse Concerns Creating Opportunity For Pfizerat Seeking Alpha(Mon, May 20)
- Eyeing Business Models and Practices that are Sustainable and Value-Creating in the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- No Relief in Sight for Pain Investorsat Motley Fool(Sun, May 12)
- DURECT CORP FinancialsEDGAR Online Financials(Fri, May 10)
- Pain Therapeutics, Durect fall on Remoxy reviewAP(Fri, May 10)
- Pain Therapeutics, Durect Fall as Pfizer Evaluates Pillat Bloomberg(Fri, May 10)
- BRIEF-Pain Therapeutics down 43 pct, DURECT down 36.5 pct premarketat Reuters(Fri, May 10)
- Pfizer yet to decide on Pain Therapeutics' painkillerat Reuters(Fri, May 10)
- DURECT Announces Update on Remoxy®PR Newswire(Fri, May 10)
- DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, May 10)
- Durect Corporation Stock Downgraded (DRRX)at TheStreet(Tue, May 7)
- Durect: Pfizer Hints At Progress With Remoxyat Seeking Alpha(Fri, May 3)
- DURECT Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.21 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.19 |
|---|
Business Summary
DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms.
View More